Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows provided by operating activities:
Net (loss) income	$ (156)	$ (74)
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	232	267
Amortization of operating lease right-of-use assets	672	588
Stock based compensation	193	240
Change in deferred tax assets	12	42
Other, net	10	17
Changes in operating assets and liabilities:
Accounts receivable, net	(206)	205
Inventories	(908)	1,118
Other assets	(77)	(20)
Security deposits and other assets	0	(19)
Accounts payable	1,342	346
Accrued expenses and other liabilities	687	296
Operating lease obligations	(672)	(588)
Net cash provided by operating activities	1,129	2,418
Cash flows from investing activities:
Purchase of property and equipment	(407)	(98)
Proceeds from sale of iBio Stock	0	4
Net cash used in investing activities	(407)	(94)
Cash flows from financing activities:
Proceeds from exercise of employee stock options	13	0
Repayments (advances) under revolving credit facility	0	(101)
Repayments under finance lease obligations	(31)	(25)
Net cash used in financing activities	(18)	(126)
Net increase in cash	704	2,198
Cash at beginning of period	1,316	331
Cash at end of period	2,020	2,529
Interest paid	31	31
Income taxes paid	37	0
Supplemental disclosures of non-cash flow transactions:
Acquisition of right-of-use assets, net	1,560	1,560
Amount owed on purchase of property and equipment	$ 65	$ 0